BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 27, 2000
View Archived Issues
Oncolym development plans clarified
Read More
Dyax and Human Genome Sciences enter drug discovery agreement
Read More
AutoImmune sells rights to patent applications in Alzheimer's disease
Read More
GPC to acquire Mitotix in an all-share transaction
Read More
New study of Sandostatin for managing diarrhea to commence in the U.S. and Canada
Read More
Genzyme Transgenics expands agreement with Centocor for second monoclonal antibody
Read More
Inhibitex commences phase I/II clinical testing of treatment for S. aureus infections
Read More
Depression and anxiety, significant risk factors for hypertension
Read More
Dopamine D1 agonist improves working memory in nonhuman primate model
Read More
IND submitted by Atrix for 120-day leuprolide treatment for prostate cancer
Read More
Phase I clinical study to begin with Reolysin as cancer treatment
Read More
Hydroxamic acid-based MMP inhibitors developed at Pfizer
Read More
BASF describes new endothelin receptor antagonists and their use
Read More
Hokuriku Seiyaku scientists discover new cytokine inhibitors
Read More
Anti-HBV nucleosides designed by Korean research team
Read More
Heterocyclic leukocyte adhesion inhibitors in early development at Aventis
Read More
Schering-Plough's new H3 receptor antagonists particularly useful for allergy
Read More
Orally bioavailable gpIIb/IIIa receptor antagonist ME-3230 profiled at Japanese meeting
Read More
Kotobuki's new hypouricemic agent KT-651 inhibits biosynthesis, enhances excretion of uric acid
Read More
Siga acquires Chlamydia vaccine technology from Oregon State University
Read More
Potent and selective PDE5 inhibitor may be useful in erectile dysfunction, heart failure
Read More
Dual ACAT-inhibitory/antioxidant effects of KY-455 may be advantageous in atherosclerosis
Read More
Design of new, nonpeptide MMP inhibitors reported by Pharmacia & Upjohn at ACS meeting
Read More
ACS presentation for AMP-397A, a broad-spectrum anticonvulsant with a novel mechanism of action
Read More
AxyS and Cytovia collaborate on development of anticancer agents
Read More
Monsanto and Pharmacia & Upjohn shareholders vote to approve merger
Read More
MC-002434 identified as prototype efflux pump inhibitor for potentiating levofloxacin activity
Read More
CPMP recommends approval of Kogenate Bayer as hemophilia A treatment
Read More
